By Admin at 25 Jan 2016
Pseudomyxoma peritonei, or PMP, is considered a rare form of cancer that typically starts in your appendix (which is why it’s also called appendix cancer). It is estimated to affect about two people per million, and it’s unknown what causes this unusual cancer to occur. However, as more becomes known about this disease, doctors are discovering it is not as rare as once thought.
By Admin at 18 Jan 2016
Right now, researchers must use billions of T cells in adoptive cell therapy. However, a new “intelligent biogel” may change that, such that only millions of T cells would be required. Plus, the biogel shows promise in revolutionizing many cancer treatments.
By Admin at 11 Jan 2016
Comprehensive genetic testing may be offered for pediatric cancer patients who have a family history of cancer. However, new research suggests hereditary genetic mutations that predispose a child to cancer may be present even in children with no family history of the disease.
By Admin at 7 Jan 2016
The FDA granted accelerated approval for Darzalex, which is a first-in-class immunotherapy treatment which works by helping your immune-system cells attack cancer cells. Darzalex is approved for patients who have received at least three prior treatments for multiple myeloma, meaning the disease has become resistant to the other treatments or has progressed within a short period of time after the last treatment.
By Admin at 5 Jan 2016
Unfortunately, only about 20 percent of ovarian cancers are currently detected in the early stages. A new blood test may change that, however, according to a study by researchers at the Georgia Institute of Technology.
Current Gateway-funded clinical trials
Clinical trials funded at leading institutions worldwide
Funds one patient for one day at a Gateway-funded clinical trial